DAPT is NOT indicated for a 6-cm aortic aneurysm with mural thrombus
In patients with aortic aneurysm and secondary mural thrombus, dual antiplatelet therapy (DAPT) is not routinely indicated and should be avoided unless there is a separate cardiovascular indication requiring it. Asymptomatic patients with secondary mural thrombus (thrombus arising from underlying aortic pathology like aneurysm) are typically managed conservatively without aggressive antiplatelet therapy 1.
Key Clinical Reasoning
Why DAPT is Not Indicated
The 2022 ACC/AHA guidelines explicitly state that asymptomatic patients with secondary mural thrombus are usually managed conservatively 1. Secondary thrombus—which is what you have in an aneurysm—differs fundamentally from primary (pedunculated) thrombus. The guidelines note that "there is no evidence to support the use of prophylactic anticoagulation" for aortic atheromas 1, and this conservative approach extends to secondary mural thrombus in aneurysms.
Supporting Evidence Against DAPT
Recent high-quality research reinforces this conservative stance:
A 2025 target trial emulation of 8,325 patients undergoing standard EVAR found that DAPT provided no cardiovascular or procedural benefit but was associated with significantly increased bleeding risk (HR 1.20,95% CI 1.02-1.41) 2
A 2023 Danish registry study of 6,344 patients with abdominal aortic aneurysms without symptomatic atherosclerosis found no evidence of DAPT effectiveness in lowering ischemic events (HR 0.91,95% CI 0.73-1.17) with a trend toward higher bleeding risk (HR 1.26) 3
When to Consider Antiplatelet Therapy
Single antiplatelet therapy (SAPT) may be appropriate if:
- The patient has established atherosclerotic cardiovascular disease (coronary artery disease, prior MI, or stroke) 4
- The patient has polyvascular disease with PAD 4
- The aneurysm is being managed with endovascular repair—though even here, SAPT appears safer than DAPT 2
Anticoagulation should be reserved for:
- Primary (pedunculated) aortic thrombus in the ascending aorta or arch due to stroke risk 1
- Patients presenting with embolic events from the thrombus 1
- Independent indication for anticoagulation (e.g., atrial fibrillation with CHA2DS2-VASc ≥2) 4
Critical Pitfalls to Avoid
Do not reflexively prescribe DAPT simply because there is a thrombus—the location, type (secondary vs. primary), and symptom status matter critically
Distinguish between secondary and primary thrombus: Secondary mural thrombus in aneurysms is managed conservatively; primary pedunculated thrombus (especially in ascending aorta/arch) requires anticoagulation due to embolic stroke risk 1
Watch for embolic complications: If the patient develops limb ischemia, visceral ischemia, or stroke from embolization, management shifts to anticoagulation, endovascular intervention, or surgery 1
Consider the aneurysm size: At 6 cm, this patient likely needs surgical or endovascular repair planning regardless of the thrombus—focus on definitive aneurysm management rather than aggressive antiplatelet therapy
Recommended Management Approach
For this specific patient:
- No DAPT unless there is a separate cardiovascular indication (prior MI, stroke, coronary stents, or symptomatic PAD)
- Consider SAPT (aspirin 81-100 mg daily) only if concomitant atherosclerotic disease is present
- Focus on aneurysm surveillance or repair planning given the 6-cm size
- Monitor for embolic symptoms: new limb pain, abdominal pain, or neurological symptoms should trigger urgent imaging and consideration of anticoagulation/intervention
- Optimize cardiovascular risk factors: statin therapy for LDL-C <55 mg/dL if atherosclerotic disease present 4, blood pressure control, smoking cessation
The bleeding risk of DAPT outweighs any theoretical benefit in preventing thromboembolic events from secondary mural thrombus in an asymptomatic aneurysm patient.